{"drugs":["Eprosartan Mesylate","Teveten"],"mono":{"0":{"id":"925031-s-0","title":"Generic Names","mono":"Eprosartan Mesylate"},"1":{"id":"925031-s-1","title":"Dosing and Indications","sub":{"0":{"id":"925031-s-1-4","title":"Adult Dosing","mono":"<b>Hypertension:<\/b> 600 mg ORALLY once daily; range 400 to 800 mg ORALLY once daily or in 2 divided doses "},"1":{"id":"925031-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"925031-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hypertension<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Heart failure<br\/>"}}},"2":{"id":"925031-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Drugs that act on the renin-angiotensin system can cause injury or death to the developing fetus when used during the second and third trimesters. When pregnancy is confirmed, discontinue treatment immediately.<br\/>"},"3":{"id":"925031-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925031-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant aliskiren use in diabetic patients<\/li><li>hypersensitivity to eprosartan or any components of the formulation<\/li><\/ul>"},{"id":"925031-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- when pregnancy is detected, discontinue therapy immediately; risk of fetal toxicity<\/li><li>Cardiovascular:<\/li><li>-- symptomatic hypotension may occur in salt and\/or volume depleted patients (eg, those receiving diuretics); correct depletion prior to initiating therapy or monitor closely<\/li><li>-- patients with severe congestive heart failure may have excessive hypotension or changes in renal function, such as oliguria, progressive azotemia, and, in rare cases, renal failure or death<\/li><li>Psychiatric:<\/li><li>--increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of lithium with angiotensin receptor agonists<\/li><li>Renal:<\/li><li>-- patients with unilateral or bilateral renal artery stenosis on ACE inhibitors and other angiotensin II antagonists may have increases in BUN or serum creatinine<\/li><li>--- deterioration of renal function, including renal failure, may occur in patients who are taking NSAIDs (including selective COX-2 inhibitors) with angiotensin 2 receptor agonists; monitoring recommended<\/li><li>Concomitant use:<\/li><li>-- avoid use with RAS inhibitors<\/li><\/ul>"},{"id":"925031-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Eprosartan: D (FDA)<\/li><li>Eprosartan: D (AUS)<\/li><\/ul>"},{"id":"925031-s-3-12","title":"Breast Feeding","mono":"Eprosartan: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"925031-s-4","title":"Drug Interactions","sub":[{"id":"925031-s-4-13","title":"Contraindicated","mono":"<ul>Aliskiren (probable)<\/ul>"},{"id":"925031-s-4-14","title":"Major","mono":"<ul><li>Benazepril (established)<\/li><li>Captopril (established)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Fosinopril (established)<\/li><li>Lisinopril (established)<\/li><li>Lithium (theoretical)<\/li><li>Moexipril (established)<\/li><li>Perindopril (established)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Trandolapril (established)<\/li><li>Trimethoprim (theoretical)<\/li><\/ul>"},{"id":"925031-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Clonixin (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sulindac (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Valdecoxib (probable)<\/li><\/ul>"}]},"5":{"id":"925031-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain<\/li><li><b>Musculoskeletal:<\/b>Myalgia (1.9%)<\/li><li><b>Neurologic:<\/b>Dizziness (3.8%)<\/li><li><b>Respiratory:<\/b>Upper respiratory infection<\/li><li><b>Other:<\/b>Fatigue (1.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Edema of face (rare)<\/li><li><b>Hematologic:<\/b>Neutropenia (1.3%)<\/li><\/ul>"},"6":{"id":"925031-s-6","title":"Drug Name Info","sub":{"0":{"id":"925031-s-6-17","title":"US Trade Names","mono":"Teveten<br\/>"},"2":{"id":"925031-s-6-19","title":"Class","mono":"<ul><li>Angiotensin II Receptor Antagonist<\/li><li>Cardiovascular Agent<\/li><\/ul>"},"3":{"id":"925031-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"925031-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"925031-s-7","title":"Mechanism Of Action","mono":"Eprosartan mesylate, a non-biphenyl non-tetrazole angiotensin II receptor (AT(1)) antagonist, prevents the binding of angiotensin II to AT(1) receptor. The blocking activity of eprosartan results in vasodilation and inhibition of aldosterone secretion..<br\/>"},"8":{"id":"925031-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"925031-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 1 h to 2 h<\/li><li>Bioavailability: approximately 13%<\/li><li>Effect of food: none<\/li><\/ul>"},"1":{"id":"925031-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 308 L<\/li><li>Protein binding: approximately 98%<\/li><\/ul>"},"3":{"id":"925031-s-8-26","title":"Excretion","mono":"<ul><li>Fecal:(IV), 61%<\/li><li>Fecal: (Oral), 90%<\/li><li>Renal: (IV), 37%<\/li><li>Renal: (Oral), 7% (approximately 20% as acyl glucuronide, 80% unchanged)<\/li><li>Dialyzable: no (hemodialysis), poorly removed<\/li><\/ul>"},"4":{"id":"925031-s-8-27","title":"Elimination Half Life","mono":"approximately 20 h <br\/>"}}},"9":{"id":"925031-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>may be taken with or without food; take at the same time every day and consistently with respect to food intake <br\/>"},"10":{"id":"925031-s-10","title":"Monitoring","mono":"<ul><li>blood pressure, heart rate<\/li><li>renal function, electrolyte panel (eg; potassium, sodium)<\/li><\/ul>"},"11":{"id":"925031-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 600 MG<br\/><\/li><li><b>Teveten<\/b><br\/>Oral Tablet: 600 MG<br\/><\/li><\/ul>"},"13":{"id":"925031-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>Instruct patient to rise slowly from a sitting\/supine position, as drug may cause symptomatic hypotension.<\/li><li>This drug may cause abdominal pain, myalgia, upper respiratory infection, or fatigue.<\/li><li>Tell patient to maintain adequate hydration while taking this drug.<\/li><li>Patient may take with or without food, but drug should be taken at the same time each day and consistently with respect to food intake.<\/li><\/ul>"}}}